<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulfacetamide (topical): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulfacetamide (topical): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sulfacetamide (topical): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9919" href="/d/html/9919.html" rel="external">see "Sulfacetamide (topical): Drug information"</a> and <a class="drug drug_patient" data-topicid="12307" href="/d/html/12307.html" rel="external">see "Sulfacetamide (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9523091"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Klaron;</li>
<li>Ovace Plus;</li>
<li>Ovace Plus Wash;</li>
<li>Ovace Wash;</li>
<li>Plexion NS;</li>
<li>Sodium Sulfacetamide-Bakuchiol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10527093"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Acne Products</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Sulfonamide Derivative</span>;</li>
<li>
<span class="list-set-name">Topical Skin Product</span></li></ul></div>
<div class="block dop drugH1Div" id="F9523173"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b> Children ≥12 years and Adolescents: Topical: Lotion 10%: Apply thin film to affected area twice daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c0a233f-68f3-4266-80aa-dfbb18c0fdd4">Seborrheic dermatitis, including seborrhea sicca</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seborrheic dermatitis, including seborrhea sicca:</b> Children ≥12 years and Adolescents: Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, Lotion 9.8%: Apply to affected areas twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice daily regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Apply to affected areas 1 to 3 times daily</p>
<p style="text-indent:-2em;margin-left:4em;">Gel, Wash: Wash affected area twice with a 10- to 20-second interval between washings; repeat application twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice daily regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Shampoo: Wash hair at least twice weekly</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f63193c-2bb4-4740-9476-6b1b2a287d13">Bacterial infections, cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial infections (secondary), cutaneous:</b> Children ≥12 years and Adolescents: Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, Lotion 9.8%: Apply to affected areas twice daily for 8 to 10 days</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Apply to affected areas 1 to 3 times daily</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: Wash affected area once daily for 8 to 10 days</p>
<p style="text-indent:-2em;margin-left:4em;">Wash: Wash affected area once or twice daily for 8 to 10 days</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block doa drugH1Div" id="F9523174"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9919" href="/d/html/9919.html" rel="external">see "Sulfacetamide (topical): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b>
<b>Topical:</b> Klaron lotion, topical suspension: Apply thin film to affected area twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98a13828-1941-405e-b7de-b0c26517e282">Bacterial infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial infections:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream, Ovace Plus lotion: Apply to affected areas twice daily for 8 to 10 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Apply to affected areas 1 to 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Wash: Apply to affected areas 1 to 2 times daily for 8 to 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d080a0f4-d3cc-4ca6-a224-9f8e53409f5b">Scaling dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scaling dermatoses:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream, Ovace Plus lotion: Apply to affected areas twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice-daily regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Apply to affected areas 1 to 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Shampoo: Wash hair at least twice weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">Wash:</p>
<p style="text-indent:-2em;margin-left:6em;">Ovace Plus Wash Liquid, Ovace Plus Wash cleansing gel, Ovace wash: Wash affected areas twice with a 10- to 20-second interval between washings; repeat twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice-daily regimen.</p>
<p style="text-indent:-2em;margin-left:6em;">SEB-Prev: Wash affected areas twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice-daily regimen.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F9523137"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined; adverse events may vary based on formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Burning sensation of skin, erythema, pruritus, Stevens-Johnson syndrome, stinging of the skin, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hematologic abnormality</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Fulminant hepatic necrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Local irritation, localized edema</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Systemic lupus erythematosus</p></div>
<div class="block coi drugH1Div" id="F9523126"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known or suspected hypersensitivity to sulfonamides or any component of the formulation; kidney disease (Ovace Plus Wash [cleansing gel/liquid], Ovace Plus lotion, Ovace Plus foam, Plexion NS shampoo).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See "Warnings/Precautions" for more detail.</p></div>
<div class="block war drugH1Div" id="F9523127"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune effects: Fatalities associated with severe reactions, including drug-induced systemic lupus erythematosus, have occurred with sulfonamides (regardless of administration route).</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: Fatalities associated with severe reactions, including agranulocytosis, acute hemolytic anemia, aplastic anemia, purpura hemorrhagica, and other blood dyscrasias, have occurred with sulfonamides (regardless of route).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Fatalities associated with severe reactions, including Stevens-Johnson syndrome, systemic lupus erythematosus, toxic epidermal necrolysis, and drug fever, have occurred with sulfonamides (regardless of route). In addition, contact dermatitis, reddening, and scaling of the skin may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Fatalities associated with severe reactions, including fulminant hepatic necrosis and jaundice, have occurred with sulfonamides (regardless of route).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Skin rash or other reactions have occurred in patients with no prior history of sulfonamide hypersensitivity. Discontinue use at the first sign of hypersensitivity or rash.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Systemic absorption is increased with application to large, infected, abraded, denuded, or burned skin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For external use only; not for ophthalmic use; avoid contact with eyes and mucous membranes. Discontinue use if irritation, rash, or signs of hypersensitivity occur. Monitor closely for local irritation and/or sensitization during long-term therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Application to infected area containing nonsusceptible organisms may cause proliferation of the organism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabisulfites: Some products contain sodium metabisulfite which may cause allergic reactions in certain individuals (eg, asthmatic patients).</p>
<p style="text-indent:-2em;margin-left:4em;">• Other topical products: Not compatible with silver-containing products.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878759"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F25827573"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">APOP gel is formulated in a vehicle containing 0.5% bakuchiol, a natural compound extracted from<i> Psoralea corylifolia</i> purported to exert antimicrobial and anti-inflammatory activity, as well as reduce scarring from acne lesions.</p>
<p style="text-indent:0em;">Some generic 10% lotion products are referred to as “topical suspensions” in the manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F9523207"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ovace Plus: 10% (57 g) [contains benzyl alcohol, butylparaben, cetyl alcohol, disodium edta, ethylparaben, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ovace Plus: 9.8% (100 g [DSC]) [contains benzyl alcohol, cetyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ovace Plus Wash: 10% (355 mL) [contains benzyl alcohol, cetearyl alcohol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (355 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sodium Sulfacetamide-Bakuchiol: 10% (355 mL) [contains disodium edta, methylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, External, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ovace Plus Wash: 10% (473 mL) [contains cetearyl alcohol, edetate (edta) disodium, methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ovace Wash: 10% (180 mL, 355 mL [DSC]) [contains edetate (edta) disodium, methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (177 g, 355 g, 454 g, 480 g, 177 mL, 240 mL, 354.8 mL, 355 mL, 360 mL, 480 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klaron: 10% (118 mL) [contains disodium edta, methylparaben, propylene glycol, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ovace Plus: 9.8% (57 g) [contains benzyl alcohol, cetyl alcohol, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (118 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Shampoo, External, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ovace Plus: 10% (237 mL) [contains cetearyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plexion NS: 9.8% (237 mL) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 9.8% (237 mL); 10% (237 mL)</p></div>
<div class="block geq drugH1Div" id="F9523094"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F9523209"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Ovace Plus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per gram): $11.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Ovace Plus Wash External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $2.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Sulfacetamide Sodium (Cleans) External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $1.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Ovace Plus Wash External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $1.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Ovace Wash External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $2.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Sulfacetamide Sodium External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $0.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Klaron External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $2.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Ovace Plus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9.8% (per gram): $11.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Sulfacetamide Sodium (Acne) External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $1.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Shampoo</b> (Ovace Plus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $3.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Shampoo</b> (Plexion NS External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9.8% (per mL): $2.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614409"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For external topical use only; avoid contact with eyes and mucous membranes.</p>
<p style="text-indent:-2em;margin-left:2em;">Foam: Cleanse affected skin thoroughly and pat dry before each application. Shake well prior to use. Dispense into palm of hand. Massage into affected areas and wait 10 minutes; rinse thoroughly with water and pat dry. Alternatively, foam may remain on skin after removing any excess product.</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion: Shake lotion well prior to use; apply a thin film to affected area.</p>
<p style="text-indent:-2em;margin-left:2em;">Shampoo: Shake shampoo well prior to use. Apply to wet hair and massage vigorously into scalp; thoroughly rinse hair.</p>
<p style="text-indent:-2em;margin-left:2em;">Gel, Wash: Apply to wet hair or skin and massage into a full lather; rinse thoroughly and pat dry; repeat after 10 to 20 seconds (for seborrheic dermatitis). If skin dryness occurs, rinse off early or use less frequently. Regular shampooing after use on hair is not necessary; however, hair should be shampooed at least once weekly.</p></div>
<div class="block adm drugH1Div" id="F9523176"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> Avoid contact with eyes and mucous membranes.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, lotion, topical suspension: Shake well prior to use.</p>
<p style="text-indent:-2em;margin-left:2em;">Foam: Cleanse affected skin thoroughly and pat dry before each application. Shake well prior to use. Dispense into palm of hand. Massage into affected areas and wait 10 minutes; rinse thoroughly with water and pat dry. Alternatively, foam may remain on skin after removing any excess product.</p>
<p style="text-indent:-2em;margin-left:2em;">Shampoo: Shake well prior to use. Apply to wet hair and massage vigorously into scalp; thoroughly rinse hair.</p>
<p style="text-indent:-2em;margin-left:2em;">Wash: Apply to wet skin and massage into a full lather, rinse thoroughly with plain water, and pat dry. If skin dryness occurs, rinse off early or use less frequently. When used for scaling dermatitis, regular shampooing after use is not necessary; however, hair should be shampooed at least once weekly.</p></div>
<div class="block sts drugH1Div" id="F9523146"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Cream, shampoo, Ovace Plus lotion: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Brief exposures to temperatures up to 40°C (104°F) may be tolerated provided the mean temperature does not exceed 25°C (77°F); however, such exposure should be minimized. Protect from freezing and excess heat. May darken slightly on storage; efficacy or safety is not affected. Keep tightly closed.</p>
<p style="text-indent:-2em;margin-left:2em;">Foam: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). Brief exposures to temperatures up to 40°C (104°F) may be tolerated provided the mean temperature does not exceed 25°C (77°F); however, such exposure should be minimized. Contents under pressure, do not puncture or incinerate.</p>
<p style="text-indent:-2em;margin-left:2em;">Klaron lotion, topical suspension: Store at 20°C to 25°C (68°F to 77°F). Keep tightly closed.</p>
<p style="text-indent:-2em;margin-left:2em;">Wash: May darken slightly on storage; efficacy or safety is not affected. Keep tightly closed.</p>
<p style="text-indent:-2em;margin-left:4em;">Ovace Wash, Ovace Plus Wash cleansing gel, Ovace Plus Wash liquid: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Brief exposures to temperatures up to 40°C (104°F) may be tolerated provided the mean temperature does not exceed 25°C (77°F); however, such exposure should be minimized. Protect from freezing and excess heat.</p>
<p style="text-indent:-2em;margin-left:4em;">SEB-Prev: Store at 20°C to 25°C (68°F to 77°F). Protect from freezing and excess heat.</p></div>
<div class="block usep drugH1Div" id="F53570746"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Lotion (10%): Topical treatment of acne vulgaris (FDA approved in ≥12 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Gel, Cream, Foam, Lotion (9.8%), Wash: Topical treatment of scaling dermatoses (including seborrheic dermatitis, seborrhea sicca); secondary cutaneous bacterial infections due to organisms susceptible to sulfonamides (FDA approved in ages ≥12 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Shampoo: Topical treatment of scaling dermatoses (including seborrheic dermatitis, seborrhea sicca) (FDA approved in ages ≥12 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information.</p></div>
<div class="block mst drugH1Div" id="F9523082"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Klaron may be confused with Klor-Con</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300090"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9523141"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F9523102"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. The amount of sulfacetamide available systemically following topical administration is unknown. Use of systemic sulfonamides during pregnancy may cause kernicterus in the newborn.</p></div>
<div class="block mopp drugH1Div" id="F53570748"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Response to therapy; signs of local irritation and/or sensitization, especially during long-term therapy. </p></div>
<div class="block pha drugH1Div" id="F9523159"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA</p></div>
<div class="block phk drugH1Div" id="F9523161"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Significant absorption through skin has been reported; percutaneous absorption about 4%.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Sulfanilamide (major metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 7 to 13 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine 0.08% to 0.33%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58207155"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dermaseb</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Anginamide | Antebor | Sulfa | Ultra</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Antebor | Sulfacetamide Dci</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Antebor</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Antebor | Ultra</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cetamide</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bleph | Ovace | Ovace plus | Re | Sodium sulfacetamide | Vanocin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sulfocil</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dermaseb</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Riacetamid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Sivex | Sulfafur</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Sulfamed</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Klaron (sulfacetamide) [prescribing information]. Bridgewater, NJ: Valent Pharmaceuticals North America LLC; May 2019.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus (sulfacetamide) foam [prescribing information]. San Antonio, TX: Mission Pharmacal Co; received January 2021.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus cream (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; October 2013.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus Cream 10% (sodium sulfacetamide) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; received February 2022.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus lotion (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; January 2015.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus Lotion 9.8% (sodium sulfacetamide) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; received February 2022.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus Shampoo 10% (sodium sulfacetamide) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; received January 2021.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus wash (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; July 2013.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus Wash cleansing gel 10% (sodium sulfacetamide) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; received August 2023.</div>
</li>
<li>
<div class="reference">
                  Ovace Plus Wash liquid (sulfacetamide) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; received August 2023.</div>
</li>
<li>
<div class="reference">
                  Ovace Wash 10% (sodium sulfacetamide) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; January 2013.</div>
</li>
<li>
<div class="reference">
                  Plexion NS Shampoo (sodium sulfacetamide 9.8%) [prescribing information]. Wilmington, DE: Eckson Labs; January 2022.</div>
</li>
<li>
<div class="reference">
                  SEB-Prev Wash (sulfacetamide topical) [prescribing information]. Minneapolis, MN: Perrigo; February 2012.</div>
</li>
<li>
<div class="reference">
                  SEB-Prev Wash 10% (sodium sulfacetamide) [prescribing information]. Minneapolis, MN: Perrigo; February 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sodium sulfacetamide 10% cleansing gel (sulfacetamide topical) [prescribing information]. Alpharetta, GA: Acella Pharmaceuticals, LLC; September 2014.</div>
</li>
<li>
<div class="reference">
                  Sodium sulfacetamide 10% lotion (sulfacetamide topical) [prescribing information]. Bridgewater, NJ: Oceanside Pharmaceuticals; June 2015.</div>
</li>
<li>
<div class="reference">
                  Sodium sulfacetamide 10% shampoo (sulfacetamide topical) [prescribing information]. San Antonio, TX: Biocomp Pharma, Inc; August 2013.</div>
</li>
<li>
<div class="reference">
                  Sulfacetamide sodium topical suspension 10% [prescribing information]. Melville, NY: E. Fougera &amp; Co; November 2007.</div>
</li>
<li>
<div class="reference">
                  Sodium sulfacetamide 10% wash (sulfacetamide topical) [prescribing information]. Fairfield, NJ: Akron Pharma Inc; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20413982">
<a name="20413982"></a>Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/20413982/pubmed" id="20413982" target="_blank">20413982</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16048 Version 206.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
